Prevalence of comorbidities and use of medication in psoriatic arthritis patients: findings from a Mexican cohort

Q3 Health Professions

Revista Colombiana de Reumatologia Pub Date : 2025-07-01 DOI:10.1016/j.rcreu.2024.03.007

David Vega-Morales , Alejandro Garza-Alpirez , María Fernanda Martínez-Guerra , Alondra Elizabeth Montoya-Montes

{"title":"Prevalence of comorbidities and use of medication in psoriatic arthritis patients: findings from a Mexican cohort","authors":"David Vega-Morales , Alejandro Garza-Alpirez , María Fernanda Martínez-Guerra , Alondra Elizabeth Montoya-Montes","doi":"10.1016/j.rcreu.2024.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Comorbidities contribute to the development of PsA and worsen disease severity. The aim of the study is to describe the clinical characteristics of Mexican PsA patients focusing on comorbidities and medications. The primary objective of our study was to investigate the clinical and epidemiological characteristics of patients with Psoriatic Arthritis (APs) who were undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs).</div></div><div><h3>Materials and methods</h3><div>We conducted a cross-sectional observational study in a secondary care clinic in northern Mexico.</div></div><div><h3>Results</h3><div>Of the total sample, 38/66 (57.5%) were women, with a mean age of 47.8 (SD 11.5) years, a mean weight of 83.8 (SD 19) kg, and BMI of 31.5 (SD 6.5) kg/m2. Smoking and alcoholism were reported in 10/66 (15.1%) and 2 (3%) of patients, respectively.</div><div>Obesity occurred in 41 (62.1%) patients, followed by diabetes mellitus in 23 (34.8%) patients, and systemic arterial hypertension in 19 (28.7%) patients. Ischaemic heart disease, heart failure, and cancer were not present in any of the patients.</div></div><div><h3>Conclusions</h3><div>0ur study revealed a higher prevalence of chronic metabolic diseases among patients with psoriatic arthritis (PsA) compared to other cohorts without inflammatory arthropathy and the Mexican population.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 3","pages":"Pages 216-221"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0121812324000641","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Comorbidities contribute to the development of PsA and worsen disease severity. The aim of the study is to describe the clinical characteristics of Mexican PsA patients focusing on comorbidities and medications. The primary objective of our study was to investigate the clinical and epidemiological characteristics of patients with Psoriatic Arthritis (APs) who were undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs).

Materials and methods

We conducted a cross-sectional observational study in a secondary care clinic in northern Mexico.

Results

Of the total sample, 38/66 (57.5%) were women, with a mean age of 47.8 (SD 11.5) years, a mean weight of 83.8 (SD 19) kg, and BMI of 31.5 (SD 6.5) kg/m2. Smoking and alcoholism were reported in 10/66 (15.1%) and 2 (3%) of patients, respectively.

Obesity occurred in 41 (62.1%) patients, followed by diabetes mellitus in 23 (34.8%) patients, and systemic arterial hypertension in 19 (28.7%) patients. Ischaemic heart disease, heart failure, and cancer were not present in any of the patients.

Conclusions

0ur study revealed a higher prevalence of chronic metabolic diseases among patients with psoriatic arthritis (PsA) compared to other cohorts without inflammatory arthropathy and the Mexican population.

查看原文本刊更多论文

银屑病关节炎患者的合并症患病率和用药情况：墨西哥队列的研究结果

合并症有助于PsA的发展，并加重疾病的严重程度。该研究的目的是描述墨西哥PsA患者的临床特征，重点关注合并症和药物治疗。本研究的主要目的是调查银屑病关节炎（APs）患者的临床和流行病学特征，这些患者正在接受生物疾病缓解抗风湿药物（bDMARDs）的治疗。材料和方法我们在墨西哥北部的一家二级保健诊所进行了一项横断面观察研究。结果女性占38/66(57.5%)，平均年龄47.8 （SD 11.5）岁，平均体重83.8 (SD 19) kg, BMI 31.5 (SD 6.5) kg/m2。吸烟和酗酒分别占10/66（15.1%）和2（3%）。肥胖41例（62.1%），糖尿病23例（34.8%），全身性动脉高血压19例（28.7%）。所有患者均未出现缺血性心脏病、心力衰竭和癌症。结论：我们的研究显示，银屑病关节炎（PsA）患者的慢性代谢性疾病患病率高于其他无炎性关节病的队列和墨西哥人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Reumatologia Medicine-Rheumatology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Colombian Journal of Rheumatology (Revista Colombiana de Reumatología) is the official organ of the Colombian Association of Rheumatology (Asociación Colombiana de Reumatología) and the Central American, Caribbean and Andean Association of Rheumatology (Asociación Centroamericana Caribe Andina de Reumatología) - ACCA. It was created in December 1993 with the purpose of disseminating scientific information derived from primary and secondary research and presenting cases coming from the practice of Rheumatology in Latin America. Since its foundation, the Journal has been characterized by its plurality with subjects of all rheumatic and osteomuscular pathologies, in the form of original articles, historical articles, economic evaluations, and articles of reflection and education in Medicine. It covers an extensive area of topics ranging from the broad spectrum of the clinical aspects of rheumatology and related areas in autoimmunity (both in pediatric and adult pathologies), to aspects of basic sciences. It is an academic tool for the different members of the academic and scientific community at their different levels of training, from undergraduate to post-doctoral degrees, managing to integrate all actors inter and trans disciplinarily. It is intended for rheumatologists, general internists, specialists in related areas, and general practitioners in the country and abroad. It has become an important space in the work of all rheumatologists from Central and South America.